US EditionGene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS
Summary by MedPage Today
2 Articles
2 Articles
All
Left
Center
1
Right
MedPage TodayReposted by 
Anti-Aging, Acupuncture and Health News
Anti-Aging, Acupuncture and Health NewsGene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS
(MedPage Today) -- CHICAGO -- Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to significantly longer disease-free survival (DFS) as compared with observation, a randomized trial showed. DFS...
·New York, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
